Keyphrases
Prostate Cancer
71%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
40%
Neoadjuvant
38%
B7 Homolog 3
37%
T Cell Receptor
37%
Immune Checkpoint Blockade
37%
Prostate-specific Antigen
29%
T Cells
28%
CD276
24%
Peptide-MHC Complex
23%
B7-H3
22%
Pan-cancer
18%
Racial Origin
18%
Clinical Characterization
18%
Immunomodulatory Response
18%
Plasmid DNA Vaccine
18%
Back to the Future
18%
Androgen Receptor
18%
Peptide Antigen
18%
Clinical Benefit
18%
Deep Learning
18%
T Cell Receptor-like Antibody
18%
Acute Promyelocytic Leukemia
18%
Androgen Deprivation Therapy
18%
Advanced Prostate Cancer
18%
Ct Value
18%
HLA-A2
18%
T Cell Antigen Recognition
18%
Oligometastatic Prostate Cancer
18%
Human Malignancies
18%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
18%
Immune Cells
18%
Transgenic Mice
18%
Small Bowel Carcinoid Tumor
18%
NY-ESO-1
18%
Extreme Response
18%
Phase II Trial
18%
Molecular Subtypes
18%
Localized Prostate Cancer
18%
Confinement Time
18%
Genomic Characterization
18%
Enzalutamide
18%
Morphological Characteristics
18%
PMHC
18%
T Cell Cross-reactivity
18%
Cross-reactivity
18%
18F-DCFPyL
18%
Therapeutic Target
18%
Tumor-specific Peptides
18%
Cell Density
18%
Immunology and Microbiology
Prostate
80%
T Cell
55%
T Cell Receptor
45%
Overall Survival
37%
Immunocompetent Cell
36%
Prostate Specific Antigen
29%
Mismatch Repair
22%
Transcriptomics
21%
Nivolumab
18%
Transgenic Mouse
18%
Exocytosis
18%
Protein Expression
18%
Ipilimumab
18%
CD276
18%
Cross-Reactivity
18%
Cell Density
18%
Enoblituzumab
18%
Cytotoxic T-Cell
17%
Exome
15%
Macrophage
15%
Antigen Response
14%
Gene Mutation
12%
Lymphocyte
12%
Antigen Presentation
12%
Mouse
10%
Notch Signaling
9%
RNA Sequencing
9%
Immune Tolerance
9%
Wnt Signaling
9%
Surface Property
9%
Signal Transduction
9%
Epithelial Mesenchymal Transition
9%
Glycoprotein
9%
Immunotherapy
8%
Programmed Death-Ligand 1
8%
Interleukin-6
7%
Progression Free Survival
7%
Failure Free Survival
7%
DNA Repair
7%
Cytokine
7%
CD4+ T Lymphocyte
6%
MSH6
6%
Immune Response
6%
Downregulation
6%
CTLA-4
6%
Mutational Load
6%
Transcriptome
6%
Natural Killer Cell
6%
Tumor-Infiltrating Lymphocytes
6%
Immune Evasion
6%
Medicine and Dentistry
Prostate Cancer
100%
Nivolumab
37%
Clinical Trial
25%
Prostate Specific Antigen
25%
Androgen Receptor
24%
Immunocompetent Cell
22%
DNA Mismatch Repair
21%
Gene Mutation
21%
Ipilimumab
18%
Clear Cell Renal Cell Carcinoma
18%
Fluorine-18
18%
Prostate Specific Membrane Antigen
18%
Acute Promyelocytic Leukemia
18%
Clinical Feature
18%
T Cell Receptor
18%
Cell Density
18%
Castration Resistant Prostate Cancer
18%
Carcinoid
18%
Positron Emission Tomography-Computed Tomography
18%
Enzalutamide
18%
Morphology
18%
T Lymphocyte
18%
T Cell
17%
Overall Survival
16%
Protein Expression
16%
Hormone Therapy
15%
Hazard Ratio
14%
Immunotherapy
14%
Androgen Deprivation Therapy
13%
Antigen Response
12%
Alkaline Phosphatase
11%
Nephrectomy
11%
Primary Tumor
11%
Immune Checkpoint Blockade
9%
Neoplasm
8%
Interleukin-6
7%
Positron Emission Tomography
7%
Cytokine
7%
Progression Free Survival
6%
Gleason Score
6%
Pembrolizumab
6%
Plasmid DNA
6%
Intraductal Carcinoma
6%
DNA Vaccine
6%
Failure Free Survival
5%
DNA Repair
5%
Metastatic Carcinoma
5%